Treg-selective IL-2 conjugateNektar Therapeutics

Rezpegaldesleukin

Rezpegaldesleukin is a regulatory-T-cell-selective IL-2 conjugate designed to restore immune balance. Nektar has evaluated it in autoimmune diseases including alopecia areata (the REZOLVE-AA study) and atopic dermatitis.

Also known as: REZPEG, NKTR-358, LY3471851

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

Rezpegaldesleukin forecasting benchmarks

1 benchmark

ResolvedPhase 2b

REZOLVE-AA (rezpegaldesleukin) Phase 2b alopecia areata

Rezpegaldesleukin · Alopecia areata

Dec 16, 2025Clinical Trials

Mechanism & molecular targets

Treg / IL-2· pathway

Indications studied

Alopecia areata· AA

Developed by

Nektar Therapeutics· NKTR

About Rezpegaldesleukin

What is Rezpegaldesleukin?

What does Rezpegaldesleukin target?

Rezpegaldesleukin acts on Regulatory T cells (IL-2 / Treg axis).

How well do AI models predict Rezpegaldesleukin trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.